Study of a new drug for advanced breast cancer after hormone therapy has stopped working
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests a new drug (HLX43) for people with a certain type of advanced breast cancer that has stopped responding to hormone therapy. The goal is to see if the drug can shrink tumors or slow the cancer's growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old
- Your breast cancer is hormone receptor positive (HR+) and HER2 negative (a specific type)
- The cancer has spread or is advanced, and you have already tried at least one line of hormone therapy and it stopped working
- Your cancer can be measured with imaging (like CT or MRI) and is not only in the bones
- You are generally able to take care of yourself (ECOG status 0 or 1) and are expected to live at least 6 more months
- You have no active or previous significant lung disease or other serious health problems that would interfere
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an investigational drug (HLX48) in people with advanced or metastatic solid tumors that have stopped responding to standard treatments. The goal is to see if it is safe and how well it works.
This trial tests an experimental drug called HLX43, given alone or with other immune-boosting drugs, for people with advanced triple-negative breast cancer (a type of breast cancer that does not have the common hormone receptors). The goal is to see if this drug can shrink tumors or slow cancer growth.
This trial tests a new drug, HLX43, for people with advanced non-small cell lung cancer that has not responded to standard treatments. It aims to see if HLX43 can help shrink or control the cancer.
This trial tests a new drug called HLX43 for people with advanced or metastatic solid tumors that have not responded to standard treatments. It aims to find safe dosing and understand how the drug works in the body.
This study tests a new pill called HLX97 for people with advanced breast, prostate, or lung cancer that has not responded to standard treatments. The goal is to find the safest dose and see if it can help slow or shrink the tumor.
This trial tests two study drugs, HLX22 and HLX87, together for people with HER2-positive breast cancer that has spread or come back. It may be an option if you haven't yet had chemotherapy or HER2-targeted therapy for advanced disease.
Hear when a new Hormone Receptor Positive HER-2 Negative Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.